Pharmacological Treatment of Acute, Experimental Spinal Cord Injury

  • Douglas K. Anderson
Part of the Neurotrauma book series (NT)


Various pharmacologic agents have been reported to be effective in the treatment of acute experimental spinal cord injury. Their mechanism(s) of action is problematic. However, based on the pathophysiology of acute spinal cord injury, it is suggested that compounds with substantial antioxidant and/or antilipolytic activity should have significant therapeutic potential for spinal cord injury. Other agents, like naloxone and TRH, may also protect a subpopulation of neurons by preventing the specific consequences of postinjury opioid elevation in spinal cord tissue. Alternatively, the megadoses required for effectiveness of all of these compounds (except U-74006F) may indicate a nonreceptor-mediated protection of damaged tissue. It is unlikely that any one drug will provide maximum protection. Rather, a combination of compounds, expeditiously administered, may be required in the clinical setting to ameloriate functional return in spinal cord injured patients.


Spinal Cord Spinal Cord Injury Thyrotropin Release Hormone Spinal Cord Tissue Acute Spinal Cord Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anderson, D.K., Braughler, J.M., Hall, E.D., Waters, T.R., McCall, J.M., Means, E.D.: Effect of treatment with U-74006F on the neurological outcome following experimental spinal cord injury. J. Neurosurg. 69:562–567, 1988b.PubMedCrossRefGoogle Scholar
  2. 2.
    Anderson, D.K., Demediuk, P., Saunders, R.D., Dugan, L.L., Means, E.D. and Horrocks, L.A.: Spinal cord injury and protection. Ann. Emerg. Med. 14:816–821, 1985.PubMedCrossRefGoogle Scholar
  3. 3.
    Anderson, D.K. and Means, E.D.: Iron-induced lipid peroxidation in spinal cord: Protection with mannitol and methylprednisolone. J. Free Radicals Biol. Med. 1:59–64, 1985.CrossRefGoogle Scholar
  4. 4.
    Anderson, D.K. and Means, E.D.: Microvascular perfusion and metabolism in injured spinal cord after methylprednisolone treatment. J. Neurosurg. 56:106–113, 1982.PubMedCrossRefGoogle Scholar
  5. 5.
    Anderson, D.K. and Means, E.D.: Pathophysiological mechanisms in acute spinal cord trauma: Effects of decompartmentalized iron on cell membranes. In: Trauma of the Central Nervous System, Dacey, R.G., Win, H.R., Rimel, R.W. and Jane, J.A., (Eds) Raven Press, New York, pp. 297–308, 1985.Google Scholar
  6. 6.
    Anderson, D.K., Waters, T.R. and Means, E.D.: Pretreat-ment with alpha-tocopherol enhances neurological recovery after experimental spinal cord compression injury. J. Neurotrauma. 5:61–68, 1988a.PubMedCrossRefGoogle Scholar
  7. 7.
    Arias, M.J.: Treatment of experimental spinal cord injury with TRH, naloxone and dexamethasone. Surg. Neurol. 28:335–338, 1987.PubMedCrossRefGoogle Scholar
  8. 8.
    Black, P. and Markowitz, R.S.: Experimental spinal cord injury in monkeys: Comparison of steroids and local hypothermia. Surg. Forum. 22:409–411, 1971.PubMedGoogle Scholar
  9. 9.
    Black, P., Markowitz, R.S., Keller, S., Wachs, K., Gillespe, J. and Finkelstein, S.D.: Naloxone and experimental spinal cord injury: Part 1. High dose administration in a static load compression model. Neurosurgery 19:905–908, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Black, P., Markowitz, R.S., Keller, S., Wachs, K., Gillespe, J., and Finkelstein, S.D.: Naloxone and experimental spinal cord injury: Part 2. Megadose treatment in a dynamic load injury model. Neurosurgery 19:909–913, 1986.PubMedCrossRefGoogle Scholar
  11. 11.
    Blackwell, G.J. and Flower, R.J.: Inhibition of phos-pholipase. Brit. Med. Bull. 39:260–264, 1983.PubMedGoogle Scholar
  12. 12.
    Bracken, M.B., Collins, W.F., Freeman, D.F., Shepard, M.J., Wagner, F.W., Silten, R.M., Hellenbrand, K.G., Ransohoff, J., Hunt, W.E., Perot, P., Grossman, R.G., Green, B.A., Eisenberg, H.M., Rifleinson, N., Goodman, J.H., Meagher, J.N., Fischer, B., Clifton, G.L., Flamm, E.S., and Rawe, S.E.: Efficacy of methylprednisolone in acute spinal cord injury. JAMA 251:45–52, 1984.PubMedCrossRefGoogle Scholar
  13. 13.
    Braughler, J.M., Chase, R.L., Neff, G.L., Yonkers, P.A., Day, J.S., Hall, E.D., Sethy, V.H. and Lahti, R.A.: A new 12-aminosteroid antioxidant lacking glucocorticoid activity blocks arachidonic acid release and stimulates ACTH secretion from mouse pituitary tumor (AtT-20) cells. J. Pharmacol. Exp. Ther. 244:423–427, 1988.PubMedGoogle Scholar
  14. 14.
    Braughler, J.M. and Hall, E.D.: Correlation of methylprednisolone levels in cat spinal cord with its effect on (Na, K)-ATPase, lipid peroxidation, and alpha motor neuron function. J. Neurosurg. 56:838–844, 1982.PubMedCrossRefGoogle Scholar
  15. 15.
    Braughler, J.M. and Hall, E.D.: Current application of “high dose” steroid therapy for CNS injury. A pharmacological perspective. J. Neurosurg. 62:806–810, 1985.PubMedCrossRefGoogle Scholar
  16. 16.
    Braughler, J.M. and Hall, E.D.: Effects of multidose methylprednisolone sodium succinate administration on injured cat spinal cord neurofilament degradation and energy metabolism. J. Neurosurg. 61:290–295, 1984.PubMedCrossRefGoogle Scholar
  17. 17.
    Braughler, J.M., Hall, E.D., Means, E.D., Waters, T.R. and Anderson, D.K. Evaluation of an intensive methylprednisolone sodium succinate dosing regimen in experimental spinal cord injury. J. Neurosurg. 67:102–105, 1987.PubMedCrossRefGoogle Scholar
  18. 18.
    Braughler, J.M., Pregenzer, J.F., Chase, R.L., Duncan, L.A., Jacobsen, E.J., and McCall, J.M.: Novel 21-aminosteroids as potent inhibitors of iron-dependent lipid peroxidation. J. Biol. Chem. 262:10438–10440, 1987.PubMedGoogle Scholar
  19. 19.
    Cao, Y.Z., Choy, P.C. and Chan, A.C.: Regulation by vitamin E of phosphatidylcholine metabolism in rat heart. Biochem. J. 247:135–140, 1987.PubMedGoogle Scholar
  20. 20.
    Clendenon, N.R., Allen, N., Gordon, W.H. and Bingham, W.G.: Inhibition of Na, K-ATPase activity following experimental spinal cord trauma. J. Neurosurg. 49:563–568, 1978.PubMedCrossRefGoogle Scholar
  21. 21.
    de la Torre, J.C., Johnson, C.M., Goode, D.J., and Mullan, S.: Pharmacologic treatment and evaluation of permanent experimental spinal cord trauma. Neurology 25:508–514, 1975.CrossRefGoogle Scholar
  22. 22.
    de la Torre, J.C., Kawanaga, H.M., Rowed, D.W., Johnson, C.M., Goode, D.J., Kajihara, K. and Mullan, S.: Dimethyl sulfoxide in central nervous system trauma. Ann. NY Acad. Sci. 243:362–389, 1975.PubMedCrossRefGoogle Scholar
  23. 23.
    Demediuk, P., Daly, M.P. and Faden, A.I.: Changes in free fatty acids, phospholipids, and cholesterol following impact injury to the rat spinal cord. Submitted to J. Neurochem., 1988.Google Scholar
  24. 24.
    Demediuk, P., Dugan, L., Means, E.D., and Horrocks, L.: Methylprednisolone and membrane properties of neurons in culture. Trans. Am. Soc. Neurochem. 16:292, 1985 (abst).Google Scholar
  25. 25.
    Demediuk, P. and Faden, A.I.: Traumatic spinal cord injury in rats causes increases in tissue thromboxane but not peptidoleukotrienes. J. Neurosci. Res. 20:115–121, 1988.PubMedCrossRefGoogle Scholar
  26. 26.
    Demediuk, P., Saunders, R.D., Anderson, D.K., Means, E.D. and Horrocks, L.A.: Membrane lipid changes in laminectomized and traumatized cat spinal cord. Proc. Nat. Acad. Sci. USA 82:7071–7075, 1985a.PubMedCrossRefGoogle Scholar
  27. 27.
    Demediuk, P., Saunders, R.D., Clendenon, R.D., Dugan, L.L., Means, E.D., Anderson, D.K. and Horrocks, L.A.: Changes in lipid metabolism in traumatized spinal cord. Prog. Brain Res. 63:211–226, 1985 b. Demopoulos, H.B., Flamm, E.S., Pietronigro, D.D. and Seligman, M.L.: The free radical pathology and the microcirculation in the major central nervous system disorders. Acta. Physiol. Scand. Suppl. 492:91-119, 1980}.PubMedCrossRefGoogle Scholar
  28. 28.
    Demopoulos, H.B., Flamm, E.S., Seligman, M.L. Pietronigro, D.D., Tomasula, J. and De Crescito, V.: Further studies on free radical pathology in the major central nervous system disorders: Effects of very high doses of ethylprednisolone on the functional outcome, morphology, and chemistry of experimental spinal cord impact injury. Can. J. Physiol. Pharmacol. 60:1415–1424, 1982.PubMedCrossRefGoogle Scholar
  29. 29.
    Douglas, E.C., Chan, A.C. and Choy, P.C.: Vitamin E inhibits platelet phospholipase A2. Biochim. Biophys. Acta. 876:639–645, 1986.PubMedCrossRefGoogle Scholar
  30. 30.
    Ducker, T.B. and Hamit, H.F.: Experimental treatments of acute spinal cord injury. J. Neurosurg. 30:693–700, 1969.PubMedCrossRefGoogle Scholar
  31. 31.
    Erin, A.N., Spirin, M.M., Tabidze, L.V. and Kagan, V.E.: Formation of alpha-tocopherol complexes with fatty acids: A hypothetical mechanism of stabilization of biomembranes by vitamin E. Biochim. Biophys. Acta. 774:96–102, 1984.PubMedCrossRefGoogle Scholar
  32. 32.
    Faden, A.I.: Neuropeptides and central nervous system injury. Clinical implications. Arch. Neurol. 43:501–504, 1986.CrossRefGoogle Scholar
  33. 33.
    Faden, A.I., Chan, P.H. and Longar, S.: Alterations in lipid metabolism, Na, K-ATPase activity, and tissue water content of spinal cord following experimental traumatic injury. J. Neurochem. 48:1809–1816, 1987.PubMedCrossRefGoogle Scholar
  34. 34.
    Faden, A.I., Hill, T.G. and Kubek, M.J.: Changes in TRH immunoreactivity in spinal cord after experimental spinal injury. Neuropeptides 7:11–18, 1986.PubMedCrossRefGoogle Scholar
  35. 35.
    Faden, A.I. and Jacobs, T.P.: Effect of TRH analogs on neurologic recovery after experimental spinal trauma. Neurology 35:1331–1334, 1985.PubMedCrossRefGoogle Scholar
  36. 36.
    Faden, A.I., Jacobs, T.P. and Holaday, J.W.: Comparison of early and late naloxone treatment in experimental spinal injury. Neurology 32:677–681, 1982.PubMedCrossRefGoogle Scholar
  37. 37.
    Faden, A.I., Jacobs, T.P. and Holaday, J.W.: Opiate antagonist improves neurologic recovery after spinal injury. Science 211:493–494, 1981a.PubMedCrossRefGoogle Scholar
  38. 38.
    Faden, A.I., Jacobs, T.P., and Holaday, J.W.: Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. NEJM 305:1063–1067, 1981c.PubMedCrossRefGoogle Scholar
  39. 39.
    Faden, A.I., Jacobs, T.P., Mougey, E. and Holaday, J.W.: Endorphins in experimental spinal injury: Therapeutic effect of naloxone. Ann. Neurol. 10:326–332, 1981b.PubMedCrossRefGoogle Scholar
  40. 40.
    Faden, A.I., Jacobs, T.P., Patrick, D.H. and Smith, M.P.: Megadose corticosteroid therapy following experimental traumatic spinal injury. J. Neurosurg. 60:712–717, 1984.PubMedCrossRefGoogle Scholar
  41. 41.
    Faden, A.I., Jacobs, T.P. and Smith, M.T.: Thyrotropin-releasing hormone in experimental spinal injury: Dose response and late treatment. Neurology 34:1280–1284, 1984.PubMedCrossRefGoogle Scholar
  42. 42.
    Faden, A.I., Jacobs, T.P., Smith, M.T. and Holaday, J.W.: Comparison of thyrotropin-releasing hormone (TRH), naloxone, and dexamethasone treatments in experimental spinal injury. Neurology 33:673–678, 1983.PubMedCrossRefGoogle Scholar
  43. 43.
    Faden, A.I., Knoblach, S., Mays, C, and Jacobs, T.P.: Motor dysfunction after spinal cord injury is mediated by opiate receptors. Peptides 6:suppl. 1, 15–17, 1985.PubMedCrossRefGoogle Scholar
  44. 44.
    Faden, A.I., Molineaux, C.J., Rosenberger, J.G., Jacobs, T.P. and Cox, B.M.: Endogenous opioid im-munoreactivity in rat spinal cord following traumatic injury. Ann. Neurol. 17:386–390, 1985b.PubMedCrossRefGoogle Scholar
  45. 45.
    Faden, A.I., Molineaux, C.J., Rosenberger, J.G., Jacobs, T.P. and Cox, B.M.: Increased dynorphin im-munoreactivity in spinal cord after traumatic injury. Regul. Pept. 11:35–41, 1985a.PubMedCrossRefGoogle Scholar
  46. 46.
    Faden, A.I., Sacksen, I. and Noble, L.J.: Structure-activity relationships of TRH analogs in rat spinal cord injury. Brain Res. 448:287–293, 1988.PubMedCrossRefGoogle Scholar
  47. 47.
    Fantone, J.C. and Ward, P.A.: Oxygen-derived radicals and their metabolites: Relationship to tissue injury. Current Concepts, A Scope Publication, The Upjohn Company, 1985.Google Scholar
  48. 48.
    Flamm, E.S., Young, W., Demopoulos, H.B., De Crescito, V. and Tomasula, J.J.: Experimental spinal cord injury: Treatment with naloxone. Neurosurgery 10:227–231, 1982.PubMedCrossRefGoogle Scholar
  49. 49.
    Green, B.A., Kahn, T. and Klose, K.J.: A comparative study of steroid therapy in acute experimental spinal cord injury. Surg. Neurol. 13:91–97, 1980.PubMedGoogle Scholar
  50. 50.
    Haghighi, S.S. and Chehrazi, B.: Effect of naloxone in experimental acute spinal cord injury. Neurosurgery 20:385–388, 1987.PubMedCrossRefGoogle Scholar
  51. 51.
    Hall, E.D.: Effects of the 21-aminosteroid U-74006F on posttraumatic spinal cord ischemia. J. Neurosurg. 68:462–465, 1988.PubMedCrossRefGoogle Scholar
  52. 52.
    Hall, E.D. and Braughler, J.M.: Effects of intravenous methylprednisolone on spinal cord lipid peroxidation and (Na, K)-ATPase activity. Dose-response analysis during 1st hour after contusion injury in the cat. J. Neurosurg. 49:563–568, 1982.Google Scholar
  53. 53.
    Hall, E.D. and Braughler, J.M.: Role of lipid peroxidation in posttraumatic spinal cord degeneration: A review. CNS Trauma 3:281–294, 1986.Google Scholar
  54. 54.
    Hall, E.D. and Wolf, D.L.: A pharmacological analysis of the pathophysiological mechanisms of posttraumatic spinal cord ischemia. J. Neurosurg. 64:951–961, 1986.PubMedCrossRefGoogle Scholar
  55. 55.
    Hall, E.D., Wolf, D.L., Althaus, J.S. and Von Voigtlander, P.F.: Beneficial effects of the k opioid receptor agonist U-50488 in experimental acute brain and spinal cord injury. Brain Res. 435:174–180, 1987.PubMedCrossRefGoogle Scholar
  56. 56.
    Hall, E.D., Wolf, D.L. and Braughler, J.M.: Effects of a single large dose of methylprednisolone sodium succinate on experimental posttraumatic spinal cord ischemia. J. Neurosurg. 61:124–130, 1984.PubMedCrossRefGoogle Scholar
  57. 57.
    Hall, E.D., Yonkers, P.A., McCall, J.M., and Braughler, J.M.: Effects of the 21-aminosteroid U-74006F on experimental head injury in mice. J. Neurosurg. 68:456–461, 1988.PubMedCrossRefGoogle Scholar
  58. 58.
    Haynes, R.C. and Murad, F.: Adrenocorticotropic hormone; adrenal steroids and their synthetic analogs, inhibitors of adrenocorticoid biosynthesis. In: Pharmacological Basis of Therapeutics. Gilman, A.G., Goodman, L.S., Gilman, A., (Eds): ed 6. New York: MacMillan, pp.1466–1496, 1980.Google Scholar
  59. 59.
    Hedeman, L.S. and Sil, R.: Studies in experimental spinal cord trauma. Part 2: Comparison of treatment with steroids, low molecular weight dextran, and catecholamine blockade. J. Neurosurg. 40:44–51, 1974.PubMedCrossRefGoogle Scholar
  60. 60.
    Hirata, F.: The regulation of lipomodulin, a phos-pholipase inhibitory protein, in rabbit neutrophils by phosphorylation. J. Biol. Chem. 256:7730–7733, 1981.PubMedGoogle Scholar
  61. 61.
    Hoerlein, B.F., Redding, R.W., Hoff, E.J., and McGuire, J.A.: Evaluation of naloxone, crocetin, thyrotropin releasing hormone, methylprednisolone, partial myelotomy and hemilaminectomy in the treatment of acute spinal cord trauma. J. Am. Anim. Hos. Assoc. 2:67–77, 1985.Google Scholar
  62. 62.
    Hoerlein, B.F. and Smith, C.W.: Functional recovery from spinal cord trauma following dexamethasone and chlorpromazine therapy in dogs. Res. Vet. Sci. 21:246–247, 1976.Google Scholar
  63. 63.
    Holaday, J.W., Tseng, L.F., Loh, H.H., and Li, C.H.: Thyrotropin releasing hormone antagonizes betaendorphin hypothermia and catalepsy. Life Sci. 22:1537–1543, 1978.PubMedCrossRefGoogle Scholar
  64. 64.
    Horrocks, L.A. and Fu, S.C.: Pathway for hydrolysis of plasmalogens in brain. In: Advances in Experimental Biology and Medicine, Vol. 101: Enzymes of lipid metabolism. Gatt, S., Freysz, L. and Mandel, P., (Eds) Plenum, New York, pp. 387–406, 1978.Google Scholar
  65. 65.
    Hsu, C.Y., Halushka, P.V., Hogan, E.L., Banik, N.L., Lee, W.A. and Perot, P.L.: Alterations of thromboxane and prostacyclin levels in experimental spinal cord injury. Neurology 35:1003–1009, 1985.PubMedCrossRefGoogle Scholar
  66. 66.
    Jonsson, H.T. and Daniell, H.B.: Altered levels of PGF in cat spina cord tissue following traumatic injury. Prostaglandins 11:51–59, 1976.PubMedGoogle Scholar
  67. 67.
    Koreh, K., Seligman, M.L., Flamm, E.S., and Demopoulos, H.B.: Lipid antioxidant properties of naloxone in vitro. Biochem. Biophys. Res. Comm. 102:1317–1322, 1981.PubMedCrossRefGoogle Scholar
  68. 68.
    Kuehl, F.A. and Egan, R.W.: Prostaglandins, arachidonic acid, and inflammation. Science 210:978–984, 1980.PubMedCrossRefGoogle Scholar
  69. 69.
    Kurihara, M.: Role of monoamines in experimental spinal cord injury in cats. Relationship between Na, K-ATPase and lipid peroxidation. J. Neurosurg. 62:743–749, 1985.PubMedCrossRefGoogle Scholar
  70. 70.
    Lewin, M.G., Hansebout, R.R. and Pappius, H.M.: Chemical characteristic of traumatic spinal cord edema in cats. Effects of steroids on potassium depletion. J. Neurosurg. 40:65–75, 1974.PubMedCrossRefGoogle Scholar
  71. 71.
    Lucy, J.A.: Functional and structural aspects of biological membranes: A suggested structural role for vitamin E in the control of membrane permeability and stability. Ann. N.Y. Acad. Sci. 203:4–11, 1972.PubMedCrossRefGoogle Scholar
  72. 72.
    Means, E.D. and Anderson, D.K.: Neuronophagia by leukocytes in experimental spinal cord injury. J. Neuropath, and Exp. Neurol. 42:707–719, 1983.CrossRefGoogle Scholar
  73. 73.
    Means, E.D., Anderson, D.K., Demediuk, P., Saunders, R.D. and Horrocks, L.A. Inflammation in experimental spinal cord injury. Exp. Brain Res. Suppl 1., 13:74–87, 1986.CrossRefGoogle Scholar
  74. 74.
    Means, E.D., Anderson, D.K., Waters, T.R. and Kalaf, L.: Effect of methylprednisolone in compression trauma to the feline spinal cord. J. Neurosurg. 55:200–208, 1981.PubMedCrossRefGoogle Scholar
  75. 75.
    Metz, R., Giebler, C. and Forster, W.: Evidence for a direct inhibitory effect of glucocorticoids on the activity of phospholipase A2 as a further possible mechanism of some actions of steroid anti-inflammatory drugs. Pharm. Res. Comm. 12:817–827, 1980.CrossRefGoogle Scholar
  76. 76.
    Milvey, P., Kakari, S., Campbell, J.B. and Demopoulos, H.B.: Paramagnetic species and radical products in cat spinal cord. Ann. N.Y. Acad. Sci. 222:1102–1111, 1973.CrossRefGoogle Scholar
  77. 77.
    Panganamala, R.V., Sharma, H.M. and Heikkila, R.E.: Role of hydroxyl radical scavengers, dimethyl sulfoxide, alcohols and methional in the inhibition of prostaglandin synthesis. Prostaglandins 11:599–604, 1976.PubMedGoogle Scholar
  78. 78.
    Parker, A.J. and Smith, C.W.I Functional recovery from spinal cord trauma following dexamethasone and chlorpromazine therapy in dogs. Res. Vet. Sci. 21:246–247, 1976.PubMedGoogle Scholar
  79. 79.
    Pietronigro, D.D., Hovsepian, M., Demopoulos, H.B., Flamm, E.S.: Loss of ascorbic acid from injured feline spinal cord. J. Neurochem. 41:1072–1076, 1983.PubMedCrossRefGoogle Scholar
  80. 80.
    Salzman, S.K., Knight, P.B., Hirofuji, E., Llados-Eckman, C., Beckman, A.L. and Winokur, A.: Spinal cord immunoreactive TRH is altered after local traumatic injury. Peptides 8:247–250, 1987.PubMedCrossRefGoogle Scholar
  81. 81.
    Saunders, R.D., Dugan, L.D., Demediuk, P., Means, E.D., Horrocks, L.A. and Anderson, D.K.: Effects of methylprednisolone and the combination of alpha-tocopherol and selenium on arachidonic acid metabolism and lipid peroxidation in traumatized spinal cord tissue. J. Neurochem. 49:24–31, 1987.PubMedCrossRefGoogle Scholar
  82. 82.
    Seligman, M.L., Mitamura, J., Shera, N. and Demopoulos, H.B.: Corticosteroid (methylprednisolone) modulation of photoperoxidation by ultraviolet light in liposomes. Photochem. Photobiol. 29:549–558, 1979.CrossRefGoogle Scholar
  83. 83.
    Smith, J.C.P., Schreier-Muccilo, S. and Marsh, D.: Spin labeling, in Pryor WA (ed). Free Radicals in Biology, New York Academic Press, Vol. 1, pp.149–197, 1976.CrossRefGoogle Scholar
  84. 84.
    Steiner, M.: Vitamin E changes the membrane fluidity of human platelets. Biochim. Biophys. Acta 640:100–105, 1981.PubMedCrossRefGoogle Scholar
  85. 85.
    Wallace, M.C. and Tator, C.H.: Failure of blood transfusion of naloxone to improve clinical recovery after experimental spinal cord injury. Neurosurgery 19:489–494, 1986.PubMedCrossRefGoogle Scholar
  86. 86.
    Ward, P.A., Till, G.D. and Kunkel, R.: Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J. Clin. Invest. 72:789–801, 1976.CrossRefGoogle Scholar
  87. 87.
    Young, W. and Flamm, E.S.: Effects of high dose corticosteroid therapy on blood flow, evoked potentials, and extracellular calcium in experimental spinal injury. J. Neurosurg. 57:667–673, 1982.PubMedCrossRefGoogle Scholar
  88. 88.
    Young, W., Flamm, E.S., Demopoulos, H.B., Tomasula, J.J. and De Crescito, V.: Effect of naloxone on posttraumatic ischemia in experimental spinal contusion. J. Neurosurg. 55:209–219, 1981.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1990

Authors and Affiliations

  • Douglas K. Anderson
    • 1
  1. 1.Cincinnati VA Med. Ctr. & Dept. of NeurologyUniversity of Cincinnati, College of MedicineUSA

Personalised recommendations